AC Immune SA Stock price

Equities

ACIU

CH0329023102

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
3.03 USD +6.69% Intraday chart for AC Immune SA -6.91% -39.40%
Sales 2024 * 12.49M 13.79M Sales 2025 * 60.77M 67.11M Capitalization 258M 285M
Net income 2024 * -62M -68.47M Net income 2025 * -24M -26.5M EV / Sales 2024 * 20.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.24 x
P/E ratio 2024 *
-4.3 x
P/E ratio 2025 *
-11.8 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.69%
1 week-6.91%
Current month-16.30%
1 month-20.05%
3 months-39.03%
6 months+1.00%
Current year-39.40%
More quotes
1 week
2.65
Extreme 2.65
3.21
1 month
2.65
Extreme 2.65
4.03
Current year
2.55
Extreme 2.55
5.04
1 year
1.78
Extreme 1.78
5.14
3 years
1.68
Extreme 1.68
12.61
5 years
1.68
Extreme 1.68
13.00
10 years
1.68
Extreme 1.68
19.97
More quotes
Managers TitleAgeSince
Founder 66 03-02-12
Director of Finance/CFO 35 18-12-31
Chief Tech/Sci/R&D Officer 42 23-09-30
Members of the board TitleAgeSince
Chairman 66 17-12-31
Director/Board Member 70 20-11-19
Director/Board Member 56 18-07-05
More insiders
Date Price Change Volume
24-03-27 3.03 +6.69% 193,211
24-03-26 2.84 -2.07% 984,868
24-03-25 2.9 -5.54% 207,722
24-03-22 3.07 -2.54% 260,750
24-03-21 3.15 -3.23% 128,159

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer's disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.743 CHF
Average target price
9.206 CHF
Spread / Average Target
+235.58%
Consensus
  1. Stock
  2. Equities
  3. Stock AC Immune SA - Nasdaq